Darzalex
Sponsors
Thomas Lund, Nantes University Hospital, Biocad, Shanghai Henlius Biotech, Qilu Pharmaceutical Co., Ltd.
Conditions
Adult Patients With Adverse Risk Acute Myeloblastic LeukemiaHealthyMultiple MyelomaNewly Diagnosed Multiple Myeloma
Phase 1
Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)
RecruitingNCT05749276
Start: 2025-02-06End: 2028-08-06Target: 12Updated: 2026-06-25
A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects
CompletedNCT05974969
Start: 2023-05-17End: 2023-08-15Updated: 2023-11-18
A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects
Not yet recruitingNCT07400744
Start: 2026-03-01End: 2026-10-01Target: 102Updated: 2026-02-10
Phase 3
A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma
RecruitingNCT06296121
Start: 2023-12-21End: 2026-07-31Target: 252Updated: 2024-03-06
A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
Not yet recruitingNCT06895512
Start: 2025-04-30End: 2027-07-31Target: 386Updated: 2025-03-26